204 related articles for article (PubMed ID: 25865949)
1. Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study.
Walley RJ; Smith CL; Gale JD; Woodward P
Pharm Stat; 2015; 14(3):205-15. PubMed ID: 25865949
[TBL] [Abstract][Full Text] [Related]
2. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
3. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
4. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
6. A practical guide to Bayesian group sequential designs.
Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H
Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian dose finding design for dual endpoint phase I trials.
Loke YC; Tan SB; Cai Y; Machin D
Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
[TBL] [Abstract][Full Text] [Related]
8. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
9. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial design for drug combinations with Bayesian model averaging.
Jin IH; Huo L; Yin G; Yuan Y
Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
[TBL] [Abstract][Full Text] [Related]
11. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
[TBL] [Abstract][Full Text] [Related]
12. Bayesian analysis of data from single case designs.
Rindskopf D
Neuropsychol Rehabil; 2014; 24(3-4):572-89. PubMed ID: 24365037
[TBL] [Abstract][Full Text] [Related]
13. A flexible mixed-effect negative binomial regression model for detecting unusual increases in MRI lesion counts in individual multiple sclerosis patients.
Kondo Y; Zhao Y; Petkau J
Stat Med; 2015 Jun; 34(13):2165-80. PubMed ID: 25784219
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
15. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
Daimon T; Zohar S; O'Quigley J
Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
[TBL] [Abstract][Full Text] [Related]
16. Bayesian noninferiority test for 2 binomial probabilities as the extension of Fisher exact test.
Doi M; Takahashi F; Kawasaki Y
Stat Med; 2017 Dec; 36(30):4789-4803. PubMed ID: 28960376
[TBL] [Abstract][Full Text] [Related]
17. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
Mayo MS; Gajewski BJ
Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
[TBL] [Abstract][Full Text] [Related]
18. Addressing potential prior-data conflict when using informative priors in proof-of-concept studies.
Mutsvari T; Tytgat D; Walley R
Pharm Stat; 2016; 15(1):28-36. PubMed ID: 26762570
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
Gönen M
Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
[TBL] [Abstract][Full Text] [Related]
20. Decision-making in early clinical drug development.
Frewer P; Mitchell P; Watkins C; Matcham J
Pharm Stat; 2016 May; 15(3):255-63. PubMed ID: 26991401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
